{
  "@context": "https://tradecompliancerecords.com/schemas/v2/regulation.json",
  "schema_version": "2.2.0",
  "open_data": true,
  "ai_optimized": true,
  "slug": "us-fda-anda",
  "name": "FDA Abbreviated New Drug Application (ANDA) — Generic Drugs",
  "authority": "FDA",
  "region": "US",
  "cluster": "pharmaceutical",
  "wikidata_qid": null,
  "wikidata_entity": null,
  "wikipedia_article": null,
  "official_source_url": "https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda",
  "gov_entry_url": null,
  "document_types": null,
  "key_obligations": null,
  "enforcement_bodies": null,
  "penalty_ranges": null,
  "affected_hs_codes": null,
  "mandatory_deadline": null,
  "applicability_scope": "Generic drug manufacturers seeking US market approval",
  "cryptographic_integrity": {
    "sha256_hash": "8ad8dfbf8c3efd216929bfa0f47a8b8dcca3febb33f84b466b379d871675e54b",
    "hash_algorithm": "SHA-256",
    "status": "cryptographically_hardened",
    "source_document_verified": true,
    "provenance": "source_document",
    "provenance_note": "SHA-256 derived from an ingested source document.",
    "r2_key": "regulations/us-fda-anda/us-fda-anda.html",
    "pdf_url": "https://tcr-vault.tradecompliancerecords.com/regulations/us-fda-anda/us-fda-anda.html",
    "file_size_bytes": 43701,
    "version_date": "2026-05-24",
    "last_verified_at": "2026-05-24T14:01:37.159Z"
  },
  "operational_consequences": null,
  "logistical_liability_exposure": false,
  "verification_consensus_score": "0",
  "verification_notes": null,
  "tcr_authority_page": "https://tradecompliancerecords.com/wiki/us-fda-anda",
  "created_at": "2026-05-20 08:54:19",
  "infographic_r2_key": null,
  "infographic_sha256_hash": null,
  "infographic_generated_at": null,
  "infographic_approved": 0,
  "origin_problem": "FACTUAL: 1984 Hatch-Waxman Act (US) aimed to balance patent protection and generic drug market entry.",
  "problem_statement": "HEADLINE: Generic drug approval lacked efficiency, delaying market entry and competition.",
  "pre_regulation_status_quo": "FACTUAL: No streamlined process for generic drug approval. Each application required full clinical trials.",
  "operational_pain_points": [
    "ANDA submission fee: $196,868 (FY 2023, FDA)",
    "Average review time: 10 months (FDA 2023 data)",
    "Bioequivalence studies: mandatory for approval (21 CFR 320)",
    "Labeling requirements: must match reference listed drug (21 CFR 314.94)",
    "Patent certification: required under 21 USC 355(j)(2)(A)(vii)"
  ],
  "search_intent_tree": null,
  "paa_questions": [
    {
      "q": "What are the penalties for non-compliance with FDA Abbreviated New Drug Application (ANDA) — Generic Drugs?",
      "a": "• Max penalty: Not publicly specified\n• Trigger: Submission of false information (21 USC 331)\n• Enforcement body: FDA\n• First offence vs repeat: Not publicly specified"
    },
    {
      "q": "Who must comply with FDA Abbreviated New Drug Application (ANDA) — Generic Drugs?",
      "a": "• Threshold: Not publicly specified\n• Entity types: Generic drug manufacturers\n• Exemptions: Not publicly specified\n• Geographic scope: US"
    },
    {
      "q": "What is the compliance deadline for FDA Abbreviated New Drug Application (ANDA) — Generic Drugs?",
      "a": "• Phase 1 deadline: Not publicly specified\n• Phase 2 deadline: Not publicly specified\n• Transitional period: Not publicly specified\n• Enforcement start: Ongoing since 1984"
    },
    {
      "q": "What documents are required for FDA Abbreviated New Drug Application (ANDA) — Generic Drugs compliance?",
      "a": "• Application form: ANDA submission (21 CFR 314.94)\n• Bioequivalence study: Demonstrate equivalence (21 CFR 320)\n• Retention period: Not publicly specified\n• Submission format: Electronic (eCTD format)"
    },
    {
      "q": "How does FDA Abbreviated New Drug Application (ANDA) — Generic Drugs affect importers?",
      "a": "• Importer obligation: Compliance with FDA approval (21 CFR 314)\n• Customs declaration requirement: Not publicly specified\n• Due diligence or traceability requirement: Not publicly specified\n• Cost estimate: Not publicly specified"
    },
    {
      "q": "What is the enforcement mechanism for FDA Abbreviated New Drug Application (ANDA) — Generic Drugs?",
      "a": "• Primary enforcer: FDA\n• Investigation trigger: Complaint or audit\n• Appeal process: 21 CFR 10.75\n• Cross-border coordination: Not publicly specified"
    },
    {
      "q": "Are there exemptions under FDA Abbreviated New Drug Application (ANDA) — Generic Drugs?",
      "a": "• SME exemption: Not publicly specified\n• Sector exclusions: Not publicly specified\n• Transitional exemptions: Not publicly specified\n• Article reference: Not publicly specified"
    },
    {
      "q": "How does FDA Abbreviated New Drug Application (ANDA) — Generic Drugs interact with other regulations?",
      "a": "• Overlaps with: Hatch-Waxman Act (US)\n• Conflicts with: Not publicly specified\n• Supersedes: Not publicly specified\n• Mutual recognition: Not publicly specified"
    },
    {
      "q": "What supply chain traceability does FDA Abbreviated New Drug Application (ANDA) — Generic Drugs require?",
      "a": "• Tier depth: Not publicly specified\n• Data fields required: Not publicly specified\n• Technology standard: Not publicly specified\n• Audit frequency: Not publicly specified"
    },
    {
      "q": "What is the cost of FDA Abbreviated New Drug Application (ANDA) — Generic Drugs compliance for a mid-size company?",
      "a": "• Implementation cost: Not publicly specified\n• Annual compliance cost: Not publicly specified\n• Penalty risk: Not publicly specified\n• Source: Not publicly specified"
    }
  ],
  "enrichment_status": "enriched"
}